Table 1 Patient characteristics according to history of papules, plaques or tumors (PPT).

From: Long-term outcomes and clinical phenotypes associated with best response to low dose alemtuzumab in cutaneous T-cell lymphoma

 

Total N

No history of PPT (TCM) N (%) 11

History of PPT (TRM/TMM) N (%) 27

Fisher’s exact p- value

Sex

F

12

1 (9.1)

11 (40.7)

0.12

M

26

10 (90.9)

16 (59.3)

Ethnicity (race)

Hispanic (unspecified)

2

1 (9.1)

1 (3.7)

0.50

Non-Hispanic (White)

36

10 (90.9)

26 (96.3)

Age > 60

No

8

8 (29.6)

0.08

Yes

30

11 (100)

19 (70.4)

Development of LCT?

10

3 (27.3)

7 (25.9)

1.0

Maximum Stage

IB-IIA

4

4

0.44

IIB

0

IIIA-IIIB

2

1

1

IVA1

30

10

20

IVA2

2

2

T-stage

T1b-T3

13

1 (9.1)

12 (44.4)

0.06

T4

25

10 (90.9)

15 (55.6)

N-stage

N0

11

4 (36.4)

7 (25.9)

0.79

N1

5

2 (18.2)

3 (11.1)

N3

2

2 (7.4)

Nx

20

5 (45.5)

15 (55.6)

M-stage

M0

38

11 (100)

27 (100)

Disease phenotype at LDA

TRM

5

5 (18.5)

<0.0001

TMM

22

22 (81.5)

TCM

11

11 (100)